Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Assess Pharmacokinetics, Safety, and Tolerability of Atumelnant in Healthy Japanese and Caucasian Participants

NCT07221084 is registered in ClinicalTrials.gov with Crinetics Pharmaceuticals Inc. as lead sponsor.

NCT NCT07221084
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07221084 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Assess Pharmacokinetics, Safety, and Tolerability of Atumelnant in Healthy Japanese and Caucasian Participants
Lead sponsor
Crinetics Pharmaceuticals Inc.
Phase
Phase 1
Overall status
Completed
Start date
October 28, 2025
Completion date
February 27, 2026
Enrollment
21 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers